Health & Medicine · Clinical Scores · Cardiovascular Risk
CHADS2 Score Calculator
Calculates the CHADS2 score for estimating annual stroke risk in patients with non-valvular atrial fibrillation.
Calculator
Formula
C = Congestive heart failure (1 point); H = Hypertension history (1 point); A = Age ≥ 75 years (1 point); D = Diabetes mellitus (1 point); S = Prior Stroke or TIA (2 points). Maximum score is 6. Higher scores indicate greater annual stroke risk.
Source: Gage BF, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870.
How it works
Atrial fibrillation is the most common sustained cardiac arrhythmia and a major independent risk factor for ischemic stroke. In AF, the irregular atrial contraction promotes blood stasis — particularly in the left atrial appendage — increasing the likelihood of thrombus formation and subsequent cardioembolic stroke. Identifying which AF patients are at elevated risk of stroke is essential for determining whether the benefits of anticoagulation outweigh the bleeding risks.
The CHADS2 acronym encodes five independent clinical risk factors: Congestive heart failure (1 point), Hypertension (1 point), Age 75 years or older (1 point), Diabetes mellitus (1 point), and prior Stroke or transient ischemic attack (TIA), which is weighted at 2 points due to its strong predictive power. The total score ranges from 0 to 6. Each additional point correlates with a progressively higher estimated annual stroke rate, derived from observed event rates in the NRAF cohort. A score of 0 carries an estimated stroke risk of approximately 1.9% per year, while a maximum score of 6 corresponds to approximately 18.2% per year.
In clinical practice, the CHADS2 score is used as a rapid bedside tool to triage AF patients. A score of 0 suggests low risk, where aspirin or no antithrombotic therapy may be appropriate. A score of 1 is considered intermediate risk, prompting consideration of anticoagulation. A score of 2 or higher generally warrants formal anticoagulation (e.g., warfarin or direct oral anticoagulants). Clinicians should always integrate this score with patient-specific factors, bleeding risk assessments (such as HAS-BLED), and shared decision-making.
Worked example
Consider a 72-year-old patient presenting with newly diagnosed atrial fibrillation. The clinical history reveals hypertension managed with an ACE inhibitor and type 2 diabetes mellitus. There is no prior stroke or TIA, no congestive heart failure, and the patient's age does not meet the 75-year threshold.
Scoring each criterion:
- Congestive Heart Failure: No → 0 points
- Hypertension: Yes → 1 point
- Age ≥ 75: No → 0 points
- Diabetes Mellitus: Yes → 1 point
- Prior Stroke or TIA: No → 0 points
Total CHADS2 Score = 0 + 1 + 0 + 1 + 0 = 2 points
A score of 2 corresponds to an estimated annual stroke risk of approximately 4.0%. According to standard clinical guidelines, this patient falls into the high-risk category and should be considered for long-term oral anticoagulation therapy, provided bleeding risk is acceptable.
Limitations & notes
The CHADS2 score has several important limitations that clinicians must consider. First, it was derived from a specific registry population in the early 2000s and may not perfectly reflect stroke rates in modern AF patients managed with contemporary therapies. Second, the score does not account for several additional risk factors now recognised as clinically relevant, including female sex, age between 65–74, and vascular disease — all of which are incorporated in the more recent CHA2DS2-VASc scoring system, which is now preferred in most international guidelines (ESC, AHA/ACC). Third, CHADS2 performs poorly at identifying truly low-risk patients: many patients with a score of 0 still experience strokes. Fourth, this tool addresses only stroke risk and must always be paired with a bleeding risk assessment (e.g., HAS-BLED) before initiating anticoagulation. It should not be used for valvular AF (e.g., mitral stenosis), where anticoagulation is universally indicated. Clinical judgment, patient preferences, and full risk-benefit assessment must always accompany the score.
Frequently asked questions
What is the difference between CHADS2 and CHA2DS2-VASc?
CHA2DS2-VASc is an expanded version of CHADS2 that adds three additional risk factors: Vascular disease (prior MI or peripheral artery disease), Age 65–74, and female Sex category. It was developed to better stratify truly low-risk patients and is now the preferred score in most international guidelines, including ESC 2020 and AHA/ACC. CHADS2 remains useful for rapid bedside risk stratification but may underestimate risk in borderline patients.
What CHADS2 score threshold indicates anticoagulation is needed?
A CHADS2 score of 2 or greater generally indicates a sufficiently high stroke risk to recommend formal anticoagulation with warfarin or a direct oral anticoagulant (DOAC). A score of 1 is considered intermediate and requires clinical judgment; a score of 0 is generally considered low risk, though many guidelines now recommend using CHA2DS2-VASc for a more refined assessment.
Why does prior stroke carry 2 points instead of 1?
Prior stroke or TIA is the single strongest independent predictor of future stroke in atrial fibrillation patients — roughly doubling the risk compared to other individual factors. The double weighting (2 points) reflects this elevated relative risk, as established in the original Gage et al. JAMA 2001 validation study using the National Registry of Atrial Fibrillation dataset.
Can CHADS2 be used in valvular atrial fibrillation?
No. CHADS2 and CHA2DS2-VASc apply only to non-valvular atrial fibrillation. Patients with valvular AF — particularly those with moderate-to-severe mitral stenosis or mechanical heart valves — carry such a high thromboembolic risk that anticoagulation is universally indicated regardless of any risk score. Vitamin K antagonists (warfarin) remain the preferred anticoagulant in mechanical valve patients, as DOACs are contraindicated in this group.
How accurate are the annual stroke risk percentages associated with CHADS2?
The stroke risk percentages are derived from observed event rates in the NRAF registry cohort studied by Gage et al. (2001). While they provide a clinically meaningful benchmark, absolute rates may differ in contemporary populations due to improved rate/rhythm control, earlier detection, and widespread anticoagulation use. They should be interpreted as approximate population-level estimates rather than precise individual predictions. The c-statistic for CHADS2 is approximately 0.62, indicating moderate discriminatory ability.
Last updated: 2025-01-15 · Formula verified against primary sources.